Research Article

Statistical Genomic Approach Identifies Association between FSHR Polymorphisms and Polycystic Ovary Morphology in Women with Polycystic Ovary Syndrome

Table 3

FSHR polymorphisms versus endocrine parameters in PCO patients.

rs2268361 valuers2349415 value
GGGAAACCCTTT

Case number1062057320215626
Age, year26.82 ± 3.9527.45 ± 3.6726.92 ± 4.520.3327.19 ± 4. 1626.96 ± 3.7028.42 ± 3.150.21
BMI, kg/m222.67 ± 4.7522.90 ± 4.9122.89 ± 3.980.9222.81 ± 4.3222.83 ± 5.1223.00 ± 5.020.98
WHR0.82 ± 0.080.83 ± 0.080.82 ± 0.070.820.82 ± 0.080.82 ± 0.070.82 ± 0.060.99
Acne score1 (0–4)0 (0–5)0 (0–5)0.070 (0–4)0 (0–5)1 (0–4)0.63
mF-G score5 (0–27)4 (0–35)3.5 (0–22)0.124 (0–35)4 (0–29)5.5 (0–16)0.33
CHOL, mmol/L4.89 ± 0.824.99 ± 0.885.04 ± 0.900.544.93 ± 0.895.01 ± 0.885.03 ± 0.690.69
TG, mmol/L1.30 ± 0.821.37 ± 0.911.22 ± 0.620.441.27 ± 0.891.27 ± 0.891.39 ± 0.760.45
HDL-C, mmol/L1.60 ± 0.421.58 ± 0.461.51 ± 0.420.421.53 ± 0.401.62 ± 0.491.56 ± 0.410.21
LDL-C, mmol/L2.81 ± 0.762.93 ± 0.843.04 ± 0.840.212.94 ± 0.842.86 ± 0.833.02 ± 0.590.58
HOMA-IR2.09 ± 1.782.45 ± 2.102.39 ± 1.910.302.29 ± 1.752.44 ± 2.322.12 ± 1.380.66
HOMA-ISI0.03 ± 0.020.03 ± 0.030.03 ± 0.020.820.03 ± 0.030.03 ± 0.020.03 ± 0.030.97
HOMA-β%120.98 ± 156.82135.70 ± 121.63136.74 ± 111.780.61125.02 ± 125.61140.06 ± 137.64135.56 ± 122.830.56
FSH, IU/L6.58 ± 2.166.65 ± 2.505.72 ± 1.900.026.31 ± 2.126.58 ± 2.656.82 ± 1.630.41
LH, IU/L11.65 ± 7.4710.62 ± 6.7310.42 ± 7.020.4110.40 ± 6.6211.26 ± 7.1712.11 ± 8.480.36
PRL, ng/mL16.05 ± 10.0217.46 ± 12.4615.04 ± 8.600.2816.11 ± 10.4416.88 ± 11.7819.19 ± 13.290.45
E2, ng/L72.88 ± 67.0963.21 ± 63.9192.84 ± 106.840.0371.16 ± 76.8371.96 ± 64.8470.74 ± 115.860.99
TT, nmol/L2.43 ± 1.242.41 ± 1.462.35 ± 0.940.922.36 ± 1.072.50 ± 1.612.09 ± 0.980.29
A2, ng/mL5.03 ± 2.205.37 ± 2.625.07 ± 2.420.715.18 ± 2.295.43 ± 2.804.34 ± 1.500.39
FT, pg/mL4.36 ± 5.625.04 ± 6.344.11 ± 3.490.414.76 ± 5.814.78 ± 5.812.92 ± 2.040.37
DHEA-S, ng/mL2124.35 ± 1049.612178.40 ± 989.352158.74 ± 1009.010.912165.36 ± 924.472206.65 ± 1103.631774.35 ± 1013.970.18
E1, pg/mL124.49 ± 71.96126.03 ± 98.9287.97 ± 57.900.29119.74 ± 73.46116.73 ± 102.42105.78 ± 72.280.91
SHBG, nmol/L76.09 ± 72.2061.64 ± 51.5053.97 ± 33.050.0356.46 ± 35.9773.13 ± 73.7171.07 ± 48.710.02
17-OHP, ng/mL1.25 ± 1.041.26 ± 0.811.33 ± 0.760.821.33 ± 0.991.22 ± 0.741.13 ± 0.500.44

Significant difference was in bold.
PCO: polycystic ovary; BMI: body mass index; WHR: waist-hip ratio; mF-G score: modified Ferriman-Gallwey score; CHOL: cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; HOMA-IR/HOMA-ISI/HOMA-β%: homeostatic model assessment for insulin resistance/insulin sensitivity/β; FSH: follicle stimulating hormone; LH: luteinizing hormone; PRL: prolactin; E2: estradiol; TT: total testosterone; A2: androstenedione; FT: free testosterone; DHEA-S: dehydroepiandrosterone sulfate; E1: estrone; SHBG: sex hormone binding globulin; 17-OHP: 17-hydroxyprogesterone.